ASH-SIE Abstract Achievement Award Recipients
The following individuals received the ASH-SIE Abstract Achievement Award, which is part of the National Partner Society Abstract Achievement Awards program.
2026 Recipients
Martina Sarchi, MD, PhD
University of Pavia
DDX54 mutations promote myelodysplastic neoplasms through nucleolar remodeling
Luca Guarnera
Department of Biomedicine and Prevention, University of Rome Tor Vergata
SETBP1 mutations define immune dysregulated transcriptional programs in myeloid neoplasms
2025 Recipients
Simona Maria Di Modica
IRCCS San Raffaele Scientific Institute
Abstract Title: Tfr2-mediated erythropoiesis expansion controls systemic glucose homeostasis by modulating erythroid metabolic demand
Marcello Turi
Candiolo Cancer Institute - Fondazione del Piemonte per L'Oncologia – IRCCS
The B2M–LILRB1 axis as a novel myeloid immune checkpoint and therapeutic target in multiple myeloma
2024 Recipients
Luca Lanino, MD
IRCCS Humanitas Research Hospital
A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
Enrica Federti
University of Verona
pkm2 Binds to the Regulatory Regions of Gata-1 and stat5 in β-Thalassemic Mouse Erythroblasts
2023 Recipients
Enrico Attardi, MD
University of Rome Tor Vergata
Unraveling the Impact of 2022 Classifications on Secondary Acute Myeloid Leukemia: Assessing the True Qualification Power of Diagnostic Qualifiers
Luca Lanino, MD
IRCCS
Molecular Classification of Chronic Myelomonocytic Leukemia: Results of the Analysis of an International Cohort of 2,471 Patients
2022 Recipients
Laura Notarfranchi, MD
University of Parma
Ultra-Sensitive Assessment of Measurable Residual Disease (MRD) in Peripheral Blood (PB) of Multiple Myeloma (MM) Patients Using Bloodflow
Giovanni Marconi, MD
IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori “Dino Amadori”(IRST),
Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia
2021 Recipients
Annamaria Aprile, PhD
IRCCS San Raffaele Scientific Institute
Inhibition of Fibroblast Growth Factor-23 (FGF-23) Rescues Bone and Hematopoietic Stem Cell Niche Defects in Beta-Thalassemia, Uncovering the Missing Link between Hematopoiesis and Bone
Abstract #572
Enrica Federti, PhD
University of Verona
Nrf2 Plays a Key Role in Iron-Overload Cardiomyopathy
Abstract #3068
2020 Recipients
Luca Bertamini, MD
GIMEMA
Poor Prognosis of Multiple Myeloma Predicted By High Levels of Circulating Plasma Cells Is Independent from Other High-Risk Features but Is Modulated By the Achievement of Minimal Residual Disease Negativity
Abstract #720
Raffaele Palmieri, MD
University of Rome Tor Vergata
Validation of ELN2017 Risk Stratification in a Post-Hoc Analysis of the Prospective Biomarker-Based Gimema AML1310 Protocol
Abstract #392
2019 Recipients
Pier Edoardo Rovatti, MD
IRCCS San Raffaele Scientific Institute
Exploiting an Anti-CD3/CD33 Bispecific Antibody to Redirect Donor T Cells Against HLA Loss Leukemia Relapses
Abstract #513
Chiara Magnanim, PhD
IRCCS San Raffaele Scientific Institute
Donor-Derived CD19 CAR Cytokine Induced Killer (CIK) Cells Engineered with Sleeping Beauty Transposon for Relapsed B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Abstract #200
2018 Recipients
Mariateresa Pettinato, MSc
IRCCS San Raffaele Scientific Institute
Inhibiting the Immunophilin FKBP12: A Potential Therapeutic Approach to Iron Overload/Low Hepcidin Disorders
Abstract #2333
Francesco Maura
University of Milan
Whole Genome Sequencing Reveals Recurrent Structural Driver Events in Peripheral T-Cell Lymphomas Not Otherwise Specified
Abstract #109
2017 Recipients
Antonella Nai, PhD
IRCCS San Raffaele Scientific Institute
The Macrophage Nuclear Receptor Coactivator 4 Counteracts Iron-Deficiency Anemia
Abstract #224
Giorgia Federico, PhD
University of Naples Federico II
NCOA4 Links Iron Bioavailability to DNA Metabolism
Abstract #223